Creative Medical Technology Holdings, Inc. (CELZ) financial statements (2021 and earlier)

Company profile

Business Address 2017 W PEORIA AVENUE
PHOENIX, AZ 85029
State of Incorp. NV
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 30414222010
Cash and cash equivalents 30414222010
Receivables 105    
Total current assets: 31418222010
Noncurrent Assets
Intangible assets, net (including goodwill) 164185101  
Intangible assets, net (excluding goodwill) 164185101   
Total noncurrent assets: 164185101   
TOTAL ASSETS: 477203323010
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 3532617117108
Accounts payable 3322386617108
Accrued liabilities 22235   
Debt 682377    
Derivative instruments and hedges, liabilities 3,2271,309    
Due to related parties 11113141144117
Other undisclosed current liabilities 198478380   
Total current liabilities: 4,4722,435454158154125
Noncurrent Liabilities
Long-term debt and lease obligation  1    
Long-term debt, excluding current maturities  1    
Liabilities, other than long-term debt  32626  
Accounts payable and accrued liabilities  31   
Due to related parties   2526  
Total noncurrent liabilities:  42626  
Total liabilities: 4,4722,439480184154125
Stockholders' equity
Stockholders' equity attributable to parent, including: (3,995)(2,236)(158)(184)(153)(125)
Common stock 903115105181818
Additional paid in capital 12,1811,075504154154154
Accumulated deficit (17,081)(3,426)(767)(356)(325)(297)
Other undisclosed stockholders' equity attributable to parent 3     
Total stockholders' equity: (3,995)(2,236)(158)(184)(153)(125)
TOTAL LIABILITIES AND EQUITY: 477203323010

Income statement (P&L) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues 1245    
Cost of revenue (70)(8)    
Gross profit: 54(3)    
Operating expenses (1,168)(1,175)(760)(21)(19)(20)
Other operating expense, net     (9)(7)
Other undisclosed operating income (loss)   (6) 97
Operating loss: (1,114)(1,178)(766)(21)(19)(20)
Nonoperating expense (12,541)(1,481)    
Interest and debt expense 408(378)(6)(10)(9)7
Loss from continuing operations before equity method investments, income taxes: (13,247)(3,037)(772)(31)(28)(13)
Other undisclosed loss from continuing operations before income taxes (408)     
Net loss: (13,656)(3,037)(772)(31)(28)(13)
Other undisclosed net income (loss) attributable to parent  3786  (14)
Net loss available to common stockholders, diluted: (13,656)(2,659)(766)(31)(28)(27)

Comprehensive Income ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (13,656)(3,037)(772)(31)(28)(13)
Comprehensive loss, net of tax, attributable to parent: (13,656)(3,037)(772)(31)(28)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: